Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Two experimental treatments for skin cancer, tailor-made to target a particular patient's tumours, proved safe in small-scale trials, their developers reported Wednesday.The vaccines also triggered an immune response to tumour cells, they said, although this does not necessarily equate to a cure.Unlike a traditional vaccine that prevents disease, the aim of NeoVax is to prevent cancer from recurring in melanoma skin cancer patients after their tumours have been surgically removed.For the time being, the team cannot conclude that their vaccine has this effect.Ott said there is already one type of cancer vaccine, for prostate cancer, on the market, but it is not widely used.The NeoVax treatment contained up to 20 neoantigens derived from patient tumours.In a second study published in the same journal, a team tested another personalised vaccine on 13 people with melanoma.
FOLLOW THIS ARTICLE